Drugs / Dexmetomidine
Dexmetomidine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT02966249 | Oct 2016 → Apr 2017 | neuromuscular disease | KAT General Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05857410 | Jan 2019 → Dec 2022 | subacute delirium | Jincheng General Hospital | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dexmetomidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05857410 ↗ |
| Known as | Dexmedetomidine | “Dexmedetomidine (DEX), a selective α2-adrenoceptor agonist, has analgesic and sedative effects and nowadays, is being studied for its adjuvant action in subarachnoid anaesthesia.” NCT02966249 ↗ |
| Known as | H20183219 | “Dexmetomidine (H20183219) 0.4μg / (kg·min)；” NCT05857410 ↗ |
| Action | Activate | “a selective α2-adrenoceptor agonist” NCT02966249 ↗ |
| Route | Intrathecal | “5 μgr dexmetomidine given intrathecally once” NCT02966249 ↗ |